AMF-triggered cancer therapy using enzyme-silica nanohybrids
Ilaria Armenia a, Beatriz Torres a, Cecilia Ortiz b, Jesús Martínez de la Fuente a c, Lorena Betancor b, Valeria Grazú a c
a Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain
b Laboratorio de Biotecnología, Universidad ORT Uruguay, Montevideo, Uruguay
c Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
Proceedings of Advanced materials and devices for nanomedicine (AMA4MED)
VALÈNCIA, Spain, 2022 May 3rd - 4th
Organizers: Claudia Tortiglione and María Moros
Contributed talk, Ilaria Armenia, presentation 020
DOI: https://doi.org/10.29363/nanoge.amamed.2022.020
Publication date: 22nd April 2022

Anti-cancer drugs are usually associated with lack of specificity and high systemic toxicity. Thus, new strategies are needed for reducing these side effects. Among them, enzyme prodrug therapy is one of the latest. It is based on the conversion of a low toxicity molecule into a cytotoxic agent only in presence of a specific enzyme.
Here, we propose an enzyme-nanoparticles hybrid that synergistically integrate the specific recognition, selectivity, and unique catalytic properties of enzymes with the size-dependent unique features of nanomaterials. In this sense, we have co-entrapped magnetic nanoparticles (MNPs) with a therapeutic enzyme (Horseradish Peroxidase, HRP) in a biomimetic silica matrix in mild and biocompatible conditions [1] to exploit the HRP activity on an innocuous pro-drugthat induces oxidative stress over tumour cells and the possibility of MNPs to generate heat under an alternative magnetic field.
The nanohybrids (nHs) display good co-entrapment efficiencies in terms of HRP immobilization (62 ± 6 %), expressed activity (79 ± 15 %) and entrapped iron (80 ± 6 %) and good catalytic properties. Besides, we assure a time-controlled activation of the enzyme, and thus of the cytotoxic effect, by a remote enzymatic nanoactuation. Indeed, in vitro results with nHs show that the system is not cytotoxic per se and displays enhanced cytotoxic activity only in the presence of the prodrug and the AMF application towards a pancreatic cancer cell line.

The research for this work has received funding from the European Union (EU) project HOTZYMES (grant agreement n° 829162) under EU’s Horizon 2020 Programme Research and Innovation actions H2020-FETOPEN-2018-2019-2020-01. Authors also thank Spanish MINECO project BIO2017-84246-C2-1-R, DGA and Fondos Feder (Bionanosurf E15_17R). Author is grateful for a predoctoral fellowship FPU (FPU19/01311).

© FUNDACIO DE LA COMUNITAT VALENCIANA SCITO
We use our own and third party cookies for analysing and measuring usage of our website to improve our services. If you continue browsing, we consider accepting its use. You can check our Cookies Policy in which you will also find how to configure your web browser for the use of cookies. More info